CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise

CRISPR Therapeutics will present data at the Annual European Hematology Association (EHA) 2022 Hybrid Congress from the Phase I dose escalation study of its CAR-T therapy in lymphoma. The product, CTX130, is currently being evaluated in two ongoing Phase I trials for relapsed or refractory renal cell carcinoma and various subtypes of lymphoma.